OC
GHDX

Oppenheimer & Co’s Genomic Health, Inc. GHDX Stock Holding History

Oppenheimer & Co’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-71,626
Closed -$2.24M – 1417
2018
Q1 		$2.24M Hold
71,626
– – 0.06% 366
2017
Q4 		$2.45M Hold
71,626
– – 0.06% 331
2017
Q3 		$2.3M Sell
71,626
-26,533
-27% -$837K 0.06% 354
2017
Q2 		$3.19M Sell
98,159
-590
-0.6% -$18.7K 0.09% 279
2017
Q1 		$3.11M Sell
98,749
-10,000
-9% -$296K 0.09% 275
2016
Q4 		$3.2M Sell
108,749
-30,000
-22% -$915K 0.09% 260
2016
Q3 		$4.01M Sell
138,749
-3,000
-2% -$83.6K 0.12% 200
2016
Q2 		$3.67M Sell
141,749
-5,000
-3% -$133K 0.11% 219
2016
Q1 		$3.63M Buy
146,749
+370
+0.3% +$10.2K 0.11% 210
2015
Q4 		$5.15M Hold
146,379
– – 0.15% 148
2015
Q3 		$3.1M Buy
146,379
+15,330
+12% +$395K 0.09% 246
2015
Q2 		$3.64M Buy
131,049
+64,556
+97% +$1.82M 0.1% 238
2015
Q1 		$2.03M Buy
66,493
+9,600
+17% +$305K 0.06% 392
2014
Q4 		$1.82M Sell
56,893
-7,000
-11% -$228K 0.05% 414
2014
Q3 		$1.81M Sell
63,893
-8,000
-11% -$223K 0.05% 409
2014
Q2 		$1.97M Buy
71,893
+11,478
+19% +$306K 0.06% 381
2014
Q1 		$1.59M Buy
60,415
+7,550
+14% +$217K 0.05% 444
2013
Q4 		$1.55M Buy
52,865
+14,880
+39% +$472K 0.05% 418
2013
Q3 		$1.16M Buy
37,985
+2,000
+6% +$66.9K 0.04% 482
2013
Q2 		$1.14M Buy
+35,985
New +$1.18M 0.04% 485

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Oppenheimer & Co's GHDX Position: Q2 2018 in Review

Oppenheimer & Co sold out of Genomic Health, Inc. (GHDX) in Q2 2018, closing a stake of 71,626 shares — an estimated $2.24M sold.

Oppenheimer & Co first reported a position in GHDX in Q2 2013 and held it in 20 quarters. The position peaked at $5.15M in Q4 2015. 166 funds tracked by Wall St. Rank hold GHDX as of Q2 2018.

  • Oppenheimer & Co reported no remaining Genomic Health, Inc. position as of Q2 2018 after selling out during the quarter.
  • Oppenheimer & Co sold 71,626 Genomic Health, Inc. shares in Q2 2018, an estimated $2.24M.
  • Oppenheimer & Co first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 20 quarters.
  • Oppenheimer & Co's Genomic Health, Inc. position peaked at $5.15M in Q4 2015.
  • 166 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2018.

Based on Oppenheimer & Co's 13F filing for Q2 2018, filed 10 Aug 2018.